Rationale for Omitted ICH E3 Topics in Clinical Study Report
FDA-hosted ICH E3 Q&A states that when a report does not address aspects of E3 that are relevant to the study, the omission should be clearly indicated and the rationale provided. Do not demand a rationale merely because sections have been reordered, renamed, deleted when warranted by study design, or new sections added; the Q&A distinguishes structural adaptation from leaving relevant content unaddressed.
ReviewedEvidence1 sourceSectionWriting & Style
Quick answer
When a relevant ICH E3 topic is not addressed, say so clearly and give the reason rather than leaving the omission implicit.
Key details
Core IssueFDA-hosted ICH E3 Q&A states that when a report does not address aspects of E3 that are relevant to the study, the omission should be clearly indicated and the rationale provided.
Registerscholarly, professional, or research/report writing
Important caveats
Scope Boundary
Do not demand a rationale merely because sections have been reordered, renamed, deleted when warranted by study design, or new sections added; the Q&A distinguishes structural adaptation from leaving relevant content unaddressed.
Further guidance
Content
Identify the relevant omitted topic and explain why it is not presented; ordinary reordering, renaming, or warranted structural adaptation is treated separately from an unexplained substantive omission.
Purpose
When a relevant ICH E3 topic is not addressed, say so clearly and give the reason rather than leaving the omission implicit.
Sources and evidence
Sources are shown with the role they play in this guide. Historical or style-sensitive claims are kept within the evidence boundary described above.
FDA-hosted ICH E3 Q&A clarifies that E3 is guidance rather than a rigid template and encourages structural adaptation when it improves display and communication of study information. Flexibility does not mean omitting relevant study information without explanation; this guide concerns report organization, not permission to weaken substantive reporting.
ICH E3 section 11.4.2.1 calls for covariate or prognostic-factor selection and adjustment to be explained, including adjustment methods, analysis results, supportive statistical documentation, and differences from planned analyses when relevant. This results-stage statistical issue is narrower than the general statistical-methods section and should not be used as a substitute for documenting the full analysis plan.
ICH E3 section 9.4.5 addresses rules or methods used to select the dose and timing of dose for individual patients. This is the patient-level dosing procedure subsection, not the preceding rationale for selecting the study doses or the later results analysis of dose-response relationships.
ICH E3 section 12.4.1 points to a by-patient listing of abnormal laboratory values in section 14.3.4 and distinguishes that safety display from the broader listing of individual laboratory measurements. This page is about the dedicated abnormal-value listing under ICH E3 14.3.4; it is distinct from the full individual-measurement appendix under 16.2.8 and from analytical discussion in section 12.4.2.
ICH E3 section 11.4.2.7 identifies special efficacy-analysis considerations for active-control studies intended to support equivalence. This is a CSR efficacy-results reporting issue for active-control equivalence designs; it does not define a universal equivalence margin or replace protocol-level design justification.
ICH E3 places patient-level adverse-event listings in the report appendices and calls for listings that identify individual patients and relevant event details supporting review. A listing is not the same as a summary adverse-event table or a selected patient narrative; each serves a different level of safety reporting.
ICH E3 section 12.3.3 calls for analysis and discussion across deaths, other serious adverse events, and other significant adverse events after the relevant case listings and narratives. This is an interpretive synthesis, not a duplicate death/serious-event listing or a replacement for individual patient narratives.
ICH E3 section 12.2.3 calls for analysis of adverse events beyond their tabular display, focusing on patterns important to safety interpretation. Do not treat the analysis as a substitute for the event display or patient-level listing, and do not imply causality beyond what the study evidence supports.
